2008   Dec, 17 Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine®   Dec, 12 Lupin appoints Divakar Kaza as President – Human Resources   Oct, 24 Lupin Q2 FY 08-09 – Strong Performance & Strategic Growth   Sept, 18 Lupin in Equity Partnership with Pharma Dynamics, South Africa   August, 21 Lupin Acquires Stake in Generic Health, Australia   August, 19 Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus® Brand in the US   July, 31 Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets   July, 30 Lupin Makes an Acquisition in Germany   July, 22 Lupin Q1, FY0809 Consolidated Net Profit up 101% to Rs. 1120 Mn   June, 26 Lupin appoints New NCE Research Head   June, 23 Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for SUPRAX® 400 mg Tablets in the U.S.   June, 16 Lupin receives USFDA approval for Escitalopram Oxalate Tablets   May, 30 Lupin receives USFDA Approval for Topiramate Tablets Lupin FY 2007-08 Consolidated Net Profit up 32% to Rs. 4083 mn   April, 28 Lupin Launches SUPRAX ®400 mg Tablets in the US   April, 23 Lupin expands its product basket in Japan   Jan, 22 Lupin Q3 FY0708 Consolidated Net Profit up 192% to Rs. 1809 Mn